Wellington Management Group LLP cut its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 25.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,915,092 shares of the company's stock after selling 1,309,593 shares during the quarter. Wellington Management Group LLP owned 1.01% of Moderna worth $162,790,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Wilmington Savings Fund Society FSB raised its holdings in Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after acquiring an additional 587 shares in the last quarter. Compass Planning Associates Inc bought a new position in shares of Moderna in the fourth quarter worth $37,000. Venturi Wealth Management LLC raised its stake in Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after purchasing an additional 664 shares in the last quarter. Crowley Wealth Management Inc. bought a new stake in Moderna during the fourth quarter worth about $41,000. Finally, MassMutual Private Wealth & Trust FSB grew its stake in Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock worth $44,000 after buying an additional 389 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.
Moderna Price Performance
Shares of MRNA traded up $0.53 during trading hours on Monday, hitting $25.64. 13,241,849 shares of the stock were exchanged, compared to its average volume of 7,069,885. The firm has a market capitalization of $9.91 billion, a P/E ratio of -2.76 and a beta of 2.23. Moderna, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $170.47. The business has a 50-day moving average of $33.23 and a 200-day moving average of $42.32.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on the stock. Argus lowered shares of Moderna from a "buy" rating to a "hold" rating in a research report on Wednesday, December 18th. Morgan Stanley dropped their price objective on Moderna from $70.00 to $38.00 and set an "equal weight" rating for the company in a research report on Wednesday, January 15th. Bank of America decreased their target price on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research report on Tuesday, February 11th. Citigroup started coverage on shares of Moderna in a report on Thursday, March 13th. They issued a "neutral" rating and a $40.00 target price for the company. Finally, Berenberg Bank upped their price objective on shares of Moderna from $33.00 to $42.00 and gave the stock a "hold" rating in a research report on Thursday, January 16th. Four investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $59.00.
View Our Latest Analysis on MRNA
Moderna Profile
(
Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
See Also
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
